FDA Approves Zytiga In Earlier Prostate Cancer Setting
This article was originally published in The Pink Sheet Daily
FDA approval of Zytiga in the pre-chemo setting gives the androgen blocker a second prostate cancer indication and another revenue stream – but a short remaining patent life and a significant competitive threat may mitigate the achievement.
You may also be interested in...
The dealmaking machine has proposed buying Dendreon’s assets, including prostate cancer immunotherapy Provenge, through a bankruptcy rummage sale.
Oncology is the biggest area of biopharmaceutical R&D where patient-reported outcomes are not routinely collected during clinical trials. There are some good reasons why. Jakafi and Zytiga remain outliers oncology treatment with a PRO in the approved label.
The once-hot biotech finally has filed for bankruptcy as it does its best to pay back note holders and looks to sell its floundering prostate cancer therapy in an effort to honor remaining employee contracts.